## **coStrands**® MOLECULAR ONCOLOGY TEST REQUISITION FORM

Please write legibly. All fields need to be completed in English. Any missing information may cause a delay in the turnaround time of the test

,	Patient Informat	ion	Treating Phys	ician Information	
Given Name		Last/Family Name	Treating Physician Information           Given Name         Last/Family Name		
Sex at Birth Date of Bir		Date of Birth (DD/MM/YYYY)	Hospital/Clinic		
Male     Female					
Address			Address		
		Countra	Postal Code	Country /	
Postal Code		Country	Postal Code	Country	
Diagnosis (please indicate specifically)		Patient ID (NRIC/Passport No.)	Telephone	Practicing Licence No.	
Stage		Primary Site	Prefer e-Report? □ Yes		
2		-	Email Required:		
Clinical History	(attached notes separately if need	ed)			
		•			
Pathology & Specimen Information					
Submitting Staff	f Name		Institution/Hospital	□ Same as above	
			De stal Ce de	Country	
Address (if different)			Postal Code	Country	
Telephone			Email		
relephone			Eman		
Date of Specimen Collection (DD/MM/YYYY)			Specimen site	Specimen ID	
In this a DELARCE case? Attach providus report (if any)			Previous lab accession no (if any	<i>\</i> ).	
Is this a 🗌 RELAPSE case? Attach previous report (if any) Previous lab accession no. (if any):					
Test Panel Selection* (tick where appropriate)					
	Essential Combined	I 🗆 DNA 68	□ Extended	□ Comprehensive	
	50 DNA + Fusion genes	68 DNA genes	109 DNA genes	523 DNA + Fusion genes	
Tissue Biopsy	Essential DNA	<ul> <li>Include Essential Fusion</li> <li>+ 18 RNA genes</li> </ul>	Include Essential Fusion + 18 RNA genes	Include HRD for Ovarian cancer only	
	Essential Fusion			□ Comprehensive Fusion	
	18 RNA genes			501 RNA genes	
		Supplementary	Toete		
Supplementary Tests					
Immunohistochemical (IHC)					
Other Tests					
Promoter Methylation  MLH1  MGMT					
*Refer to reverse for tissue specimen guidelines & requirements. Full list of genes available upon request.					
Physician's Declaration & Confirmation of Informed Consent					
I declare that the information provided is accurate and true to the best of my knowledge at the time of submission. My signature attests that I am a licensed					

medical professional and the patient's treating physician authorised to order genetic testing. I attest that the testing is medically necessary and that the test results may impact the medical management of the patient. I have also explained the purpose and limitations of the test(s) to be performed and have obtained the patient/parent/legal guardian's informed consent, to the extent required by applicable law, to allow LifeStrands Genomics (LSG) or any laboratory with which LSG has contracted to perform the test(s) specified herein, including the use & storage of samples for diagnosis, future monitoring, internal quality assurance/operations, and future unspecified research or other purposes.

Signature

Full Name

Date (DD/MM/YYYY)


For Laboratory Use Only (barcode space)

# **OncoStrands**<sup>®</sup> SPECIMEN GUIDELINES (SAMPLE TYPES & REQUIREMENTS)

## Below are recommended specimen requirements to assist in successful genomic profiling.

### Acceptable Samples (for Tissue Biopsy)

- Formalin-fixed paraffin-embedded (FFPE) specimens, including cut slide specimens, core needle biopsies, fine-needle aspirates, and effusion cytologies (cell blocks).
- Tissue SHOULD be FFPE (tissue blocks). Use standard industrial fixation method to preserve nucleic acid integrity.
- DO NOT decalcify tissue. Use EDTA if required.



#### FFPE Block Return

Return Address  $\Box$  Same as previous  $\Box$  Please send to the following:

### **Test Description**

#### **OncoStrands® Essential**

A 50-genes targeted NGS panel covering key cancer-related genes for different tumour types, including lung, colon, skin (melanoma), urinary bladder, thyroid, brain, etc. It also covers DNA hotspots from 45 genes, CNVs from 14 genes and fusions from 18 genes.

#### **OncoStrands® DNA 68**

A 68-genes hybrid capture DNA NGS panel with coverage of full coding regions of 68 key cancer-related genes (plus TERT promoter region), including BRCA1 & BRCA2. Essential Fusion selection (18 genes) can be ordered in combination with this panel if screening for fusions is clinically important.

#### **OncoStrands® Extended**

A 109-genes hybrid capture DNA NGS panel with coverage of full coding regions of 103 genes, including BRCA1 & BRCA2 and many other DNA damage repair genes (plus TERT promoter region). This assay is particularly useful for tumours in the prostate, breast, ovary & fallopian tube, pancreas, biliary tract, uterus and colon. It also provides an accurate MSI score. Essential Fusion selection (18 genes) can be ordered in combination with this panel if screening for fusions is clinically important.

#### **OncoStrands® Comprehensive / Fusion RNA**

Based on TSO500 chemistry, this assay offers a comprehensive genomic analysis across 523 genes and targets SNVs, CNVs, fusions (501 genes for compressive fusion conducted separately), splice variants, MSI and TMB. It also provides extensive coverage of NCCN biomarker testing guidelines, genes associated with FDA-approved targeted therapies and clinical trials matching for a variety of tumours.

#### Immunohistochemical (IHC) & Promoter Methylation Tests

Supplementary tests as add-ons to selected OncoStrands® panels to assist in better treatment decisions and predict outcome response to therapy.

For LifeStrands Laboratory Use ONLY					
Reception Date	Reception Time	Received By			
Sample Type		Sample ID			
Project/Clinical Trial No.		Remarks (if any)			

LifeStrands Empowering lives with Genomics